- Home
- S vs PTGX Comparison
S vs PTGX Comparison
Compare S & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | S | PTGX |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 5.4B |
| IPO Year | 2021 | 2016 |
Fundamental Metrics
Financial Performance| Metric | S | PTGX |
|---|---|---|
| Price | $14.93 | $95.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 29 | 9 |
| Target Price | $22.07 | ★ $88.33 |
| AVG Volume (30 Days) | ★ 9.7M | 953.6K |
| Earning Date | 12-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.72 |
| Revenue | ★ $955,646,000.00 | $209,217,000.00 |
| Revenue This Year | $24.41 | N/A |
| Revenue Next Year | $20.84 | $296.47 |
| P/E Ratio | ★ N/A | $132.39 |
| Revenue Growth | ★ 24.09 | N/A |
| 52 Week Low | $14.48 | $33.70 |
| 52 Week High | $25.24 | $95.39 |
Technical Indicators
Market Signals| Indicator | S | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 39.45 | 72.11 |
| Support Level | $14.48 | $88.30 |
| Resistance Level | $15.65 | $92.80 |
| Average True Range (ATR) | 0.50 | 2.80 |
| MACD | -0.07 | 0.32 |
| Stochastic Oscillator | 18.70 | 90.21 |
Price Performance
Historical ComparisonAbout S SentinelOne Inc.
SentinelOne is a cloud-based cybersecurity company specializing in endpoint protection. SentinelOne's primary offering is its Singularity platform that offers a single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The California-based firm was founded in 2013 and went public in 2021.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.